SMS (2175) Fundamentals 2026 — Revenue Analysis | SniperIQ
SMS (2175) is a JP-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥201.7B, trading at ¥2457.00 on the JPX. This SniperIQ fundamentals page covers SMS's valuation, profitability (net margin -22.1%), revenue (¥64.7B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SMS's market cap?
SMS (2175) has a market capitalization of approximately ¥201.7B, trading at ¥2457.00 on the JPX. Market cap moves with the live share price.
What is SMS's P/E ratio?
SMS's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SMS?
SMS runs a net profit margin of -22.1%, a gross margin of 81.1%, and an operating margin of 10.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SMS generate?
SMS reported revenue of ¥64.7B for fiscal year 2026, with net income of -¥14.3B and earnings per share (EPS) of -173.65. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SMS pay a dividend?
SMS offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is SMS financially healthy?
SMS carries a debt-to-equity ratio of 0.27x and a current ratio of 1.56x, with a market beta of 1.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SMS a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SMS (2175) the key facts are: market cap ¥201.7B, revenue ¥64.7B, 52-week range 1262-2623. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SMS's full fundamentals live
Get SMS's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.